Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 21, 2021 09:44 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Pharmaceuticals Project With Huntsman Cancer Institute Researcher to Investigate Potential Effects of Lasofoxifene on ESR1 Mutations in Endometrial Cancer

COLUMBUS, Ohio, April 21, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to treat ESR1-mutated metastatic...
January 07, 2021 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Pharmaceuticals Names Dr. Elizabeth Garner to Its Board of Directors

COLUMBUS, Ohio, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
December 03, 2020 10:20 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix to Present Poster on Phase 2 Study of Lasofoxifene in Combination with Eli Lilly and Company’s Abemaciclib at Virtual San Antonio Breast Cancer Symposium 2020

COLUMBUS, Ohio, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
December 02, 2020 10:25 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix to Present Poster on Patient Awareness of ESR1 Mutation Biomarker Testing, Attitudes on Metastatic Breast Cancer Quality of Life at Virtual San Antonio Breast Cancer Symposium 2020

COLUMBUS, Ohio, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
October 13, 2020 09:30 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Doses First Patient in Phase 2 Clinical Trial Collaboration Studying Lasofoxifene in Combination With Eli Lilly and Company’s Abemaciclib

COLUMBUS, Ohio, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
September 30, 2020 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Pharmaceuticals Partners With Exactis Innovation for ELAINE 1 Clinical Trial Sites in Canada

COLUMBUS, Ohio, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
September 10, 2020 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix CEO David Portman to Participate in Women’s Health Innovation Virtual Summit

COLUMBUS, Ohio, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
July 08, 2020 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lilly’s CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer

COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision...
June 18, 2020 10:06 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix to Present Poster on Lasofoxifene, CDK 4/6 Inhibitor Combination for AACR Virtual Annual Meeting

COLUMBUS, Ohio, June 18, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-focused oncology products in the...
December 03, 2019 10:00 ET | Source: Sermonix Pharmaceuticals LLC

Sermonix to Co-sponsor ‘Candid Conversations’ Patient Advocacy Panel With Breastcancer.org at San Antonio Breast Cancer Symposium

COLUMBUS, Ohio, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the...